Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to $69.1 million.

  • Neurocrine Biosciences' Other Accumulated Expenses rose 4989.15% to $69.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $69.1 million, marking a year-over-year increase of 4989.15%. This contributed to the annual value of $69.1 million for FY2025, which is 4989.15% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Other Accumulated Expenses of $69.1 million as of Q4 2025, which was up 4989.15% from $53.7 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Other Accumulated Expenses registered a high of $69.1 million during Q4 2025, and its lowest value of $18.1 million during Q1 2021.
  • In the last 4 years, Neurocrine Biosciences' Other Accumulated Expenses had a median value of $36.7 million in 2024 and averaged $36.1 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Other Accumulated Expenses surged by 2569.44% in 2021, and later surged by 9945.65% in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Other Accumulated Expenses stood at $20.0 million in 2021, then surged by 79.5% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then surged by 49.89% to $69.1 million in 2025.
  • Its Other Accumulated Expenses stands at $69.1 million for Q4 2025, versus $53.7 million for Q3 2025 and $56.8 million for Q2 2025.